Morningstar

Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors

Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
Nature

The unique contributions of adverse childhood experiences to increases in post-traumatic stress symptoms and problematic substance use after trauma exposure

This study investigated the complex relationships between adverse childhood experiences (ACE), post-traumatic stress symptoms (PTSS), and substance use disorder (SUD) following a large-scale ...